Northwestern Medicine scientists have uncovered new details explaining how poxviruses manipulate host cells to enhance their ...

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...

Visualizing cells after editing specific genes can help scientists learn new details about the function of those genes. But ...

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...